Career achievement for contributions in Physiologically based pharmacokinetic (PBPK) and biologically based does response (BBDR) modelling tools
This investment will help BSV avoid carbon dioxide emissions by as much as 6560 tonnes of carbon dioxide equivalent (tCO2e) annually over its project life of 25 years
SIFI is currently evaluating various options for the commercialization of Akantior (polihexanide) globally, including potential out-license agreements outside its core markets
The new solution, built on patented blockchain technology, dynamically adapts to patients' behaviour patterns to make clinical encounters more effective
The single in vitro diagnostic test helps inform therapy decisions according to clinical guidelines to enable precision medicine earlier in the disease journey
Feedback and remarks of the industry and stakeholders are invited till the 25th of March 2022
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
It signals Cordis' renewed investment in innovation
Lynparza is approved in the US, EU, Japan and several other countries for the treatment of patients with gBRCAm, HER2-negative, metastatic breast cancer previously treated with chemotherapy based on results from the OlympiAD Phase III trial
Subscribe To Our Newsletter & Stay Updated
